Abstract
Theranostic medicine is relatively a new term that describes integration of diagnostic and therapeutic functions within the same platform of pharmaceuticals. Such a design may in principle permit the molecular diagnosis, targeted therapy, and simultaneous monitoring and treatment necessary to achieve personalized medicine for cancer. Theranostic radiopharmaceuticals, for instance, carry the properties of both diagnostic radioimaging and radioimmunotherapy (RIT). As nuclear imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) have excellent sensitivity and can provide biochemical information on pathological conditions, much effort has been made in order to accomplish a more effective and powerful theranostic combination. Some recent examples include SPECT-therapy, PET-therapy, and therapy-therapy. In particular, the combined therapy-therapy method is the result of realization that RIT relying on a single radioisotope has an inherent limitation for practical cancer treatment. Thus the success of theranostic nuclear medicine depends on a proper choice of different radioisotopes that will lead to a perfect couple. This pair of radioisotopes is called matched-pair radioisotopes. The structural motif for radiopharmaceuticals based on matched-pair consists of a bifunctional chelator (BFCA) and a biologically active molecule (BAM). This review will focus on recent advances in radiopharmaceutical application of matched-pair radiometals in clinics as well as preclinics.
Keywords: Theranostic, radioimaging, radioimmunotherapy, bifunctional chelator, matched-pair radiometals
Current Topics in Medicinal Chemistry
Title:Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals
Volume: 13 Issue: 4
Author(s): Ji-Ae Park and Jung Young Kim
Affiliation:
Keywords: Theranostic, radioimaging, radioimmunotherapy, bifunctional chelator, matched-pair radiometals
Abstract: Theranostic medicine is relatively a new term that describes integration of diagnostic and therapeutic functions within the same platform of pharmaceuticals. Such a design may in principle permit the molecular diagnosis, targeted therapy, and simultaneous monitoring and treatment necessary to achieve personalized medicine for cancer. Theranostic radiopharmaceuticals, for instance, carry the properties of both diagnostic radioimaging and radioimmunotherapy (RIT). As nuclear imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) have excellent sensitivity and can provide biochemical information on pathological conditions, much effort has been made in order to accomplish a more effective and powerful theranostic combination. Some recent examples include SPECT-therapy, PET-therapy, and therapy-therapy. In particular, the combined therapy-therapy method is the result of realization that RIT relying on a single radioisotope has an inherent limitation for practical cancer treatment. Thus the success of theranostic nuclear medicine depends on a proper choice of different radioisotopes that will lead to a perfect couple. This pair of radioisotopes is called matched-pair radioisotopes. The structural motif for radiopharmaceuticals based on matched-pair consists of a bifunctional chelator (BFCA) and a biologically active molecule (BAM). This review will focus on recent advances in radiopharmaceutical application of matched-pair radiometals in clinics as well as preclinics.
Export Options
About this article
Cite this article as:
Park Ji-Ae and Kim Jung Young, Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals, Current Topics in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1568026611313040006
DOI https://dx.doi.org/10.2174/1568026611313040006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Dapsone-Loaded Microsponge Gel for Acne Management: Preparation, Characterization and Anti-Microbial Activity
Micro and Nanosystems Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets
Current Pharmaceutical Design Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells
Current Signal Transduction Therapy Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Design, Synthesis and Pharmacological Evaluation of Gastro- Protective Anti-inflammatory Analgesic Agents based on Dual Oxidative Stress / Cyclooxygenase Inhibition
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science Treatment for Cancer Patients with Oral Mucositis: Assessment Based on the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer in International Society of Oral Oncology (MASCC/ISOO) in 2013 and Proposal of Possible Novel Treatment with a Japanese Herbal Medicine
Current Pharmaceutical Design Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets